Generalized Anxiety Disorder

• Anxiety can be conceptualized as a normal
  and adaptive response to threat that prepares
  the organism for flight or fight
• Persons who seem to be anxious about almost
  everything, however, are likely to be classified
  as having generalized
• anxiety disorder associated with somatic
  symptoms, such as muscle tension, irritability,
  difficulty sleeping, and restlessness
• The anxiety is not focused on features of
  another Axis I disorder, is not caused by
  substance use or a general medical
  condition, and does not occur only during a
  mood or psychiatric disorder.
Epidemiology
• Generalized anxiety disorder is a common
  condition; reasonable estimates for its 1-year
  prevalence range from 3 to 8 percent.
• The ratio of women to men with the disorder is
  about 2 to 1, but the ratio of women to men who
  are receiving inpatient treatment for the disorder
  is about 1 to 1. A lifetime prevalence is close to 5
  percent with the Epidemiological Catchment Area
  (ECA) study suggesting a lifetime prevalence as
  high as 8 percent.
• In anxiety disorder clinics about 25 percent of
  patients have generalized anxiety disorder.
  The disorder usually has its onset in late
  adolescence or early adulthood, although
  cases are commonly seen in older adults
• Also, some evidence suggests that the
  prevalence of generalized anxiety disorder is
  particularly high in primary care settings
Comorbidity

• Generalized anxiety disorder coexists with
  another mental disorder, usually social
  phobia, specific phobia, panic disorder, or a
  depressive disorder
• As many as 25 percent of patients eventually
  experience panic disorder. Generalized anxiety
  disorder is differentiated from panic disorder
  by the absence of spontaneous panic attacks.
Biological Factors

• benzodiazepines and the azaspirones (e.g.,
  buspirone [BuSpar]) have focused biological
  research efforts on the γ-aminobutyric acid
  and serotonin neurotransmitter systems
• Benzodiazepines (which are benzodiazepine
  receptor agonists) are known to reduce
  anxiety
• Where as flumazenil (Romazicon) (a
  benzodiazepine receptor antagonist) and the
  β-carbolines (benzodiazepine receptor reverse
  agonists) are known to induce anxiety.
Anxiety disorder
Anxiety disorder
Anxiety disorder
Treatment

• The most effective treatment of generalized
  anxiety disorder is probably one that
  combines psychotherapeutic,
  pharmacotherapeutic, and supportive
  approaches.
Psychotherapy

• The major techniques used in behavioral approaches
  are relaxation and biofeedback
• Insight-oriented psychotherapy focuses on uncovering
  unconscious conflicts and identifying ego strengths
• Psychodynamic therapy proceeds with the assumption
  that anxiety can increase with effective treatment. The
  goal of the dynamic approach may be to increase the
  patient's anxiety tolerance (a capacity to experience
  anxiety without having to discharge it), rather than to
  eliminate anxiety
Pharmacotherapy

I.     Benzodiazepines
II.    Buspirone
III.   Venlafaxine
IV.    Selective Serotonin Reuptake Inhibitors
V.     Other drugs
Anxiety Disorder due to a General
       Medical Condition
Etiology
• A wide range of medical conditions can cause
  symptoms similar to those of anxiety disorders
  (Table 16.7-1).
  Hyperthyroidism, hypothyroidism, hypoparath
  yroidism, and vitamin B12 deficiency are
  frequently associated with anxiety symptoms
• A pheochromocytoma produces
  epinephrine, which can cause paroxysmal
  episodes of anxiety symptoms
Anxiety disorder
Anxiety disorder
Generalized Anxiety
• generalized anxiety disorder symptoms has
  been reported in patients with sjogren’s
  syndrome, and this rate may be related to the
  effects of sjogren’s syndrome on cortical and
  subcortical functions and thyroid function
• generalized anxiety disorder symptoms in a
  medical disorder seems to be in Graves'
  disease
Phobias

• 17 percent prevalence of symptoms of social
  phobia in patients with Parkinson's disease
• patients complain of a fear of falling, which
  may express itself by their being unwilling or
  fearful of walking
Differential Diagnosis

• A mental status examination is necessary to
  determine the presence of mood symptoms or
  psychotic symptoms that may suggest another
  psychiatric diagnosis
• For a clinician to conclude that a patient has an
  anxiety disorder caused by a general medical
  condition, the patient should clearly have anxiety
  as the predominant symptom and should have a
  specific causative nonpsychiatric medical disorder
Treatment

• the removal of the primary medical condition
  does not reverse the anxiety disorder
  symptoms, treatment of these symptoms
  should follow the treatment guidelines for the
  specific mental disorder
• In general, behavioral modification
  techniques, anxiolytic agents, and
  serotonergic antidepressants have been the
  most effective treatment modalities
Substance-Induced Anxiety Disorder
• Substance-induced disorder is the direct result
  of a toxic substance, including drugs of
  abuse, medication, poison, and
  alcohol, among others.
Etiology

• as amphetamine, cocaine, and caffeine, have
  been most associated with the production of
  anxiety disorder symptoms, many
  serotonergic drugs (e.g., lysergic acid
  diethylamide [LSD] and
  methylenedioxymethamphetamine [MDMA])
  can also cause both acute and chronic anxiety
  syndromes in users
• wide range of prescription medications
Anxiety disorder
Anxiety disorder
Clinical Features
• Nevertheless, alcohol use disorders and other
  substance-related disorders are commonly
  associated with anxiety disorders.
• Alcohol use disorders are about four times more
  common among patients with panic disorder
  than among the general population, about three
  and a half times more common among patients
  with OCD, and about two and a half times more
  common among patients with phobias
Course and Prognosis
• The course and prognosis generally depend on
  removal of the causally involved substance and
  the long-term ability of the affected person to
  limit use of the substance.
• The anxiogenic effects of most drugs are
  reversible.
• When the anxiety does not reverse with cessation
  of the drug, clinicians should reconsider the
  diagnosis of substance-induced anxiety disorder
  or consider the possibility that the substance
  caused irreversible brain damage.
Treatment

• anxiety disorder symptoms continue even
  after stopping substance use, treatment of the
  anxiety disorder symptoms with appropriate
  psychotherapeutic or pharmacotherapeutic
  modalities may be appropriate
Anxiety Disorder not Otherwise
           Specified
Mixed Anxiety-Depressive Disorder

• Mixed anxiety-depressive disorder describes
  patients with both anxiety and depressive
  symptoms who do not meet the diagnostic
  criteria for either an anxiety disorder or a mood
  disorder.
• The combination of depressive and anxiety
  symptoms results in significant functional
  impairment for the affected person.
• The condition may be particularly prevalent in
  primary care practices and outpatient mental
  health clinics
Diagnosis

• anxiety and depression and the presence of
  some autonomic symptoms, such as
  tremor, palpitations, dry mouth, and the
  sensation of a churning stomach.
Clinical Features

• anxiety disorders and some symptoms of
  depressive disorders are common symptoms
  of autonomic nervous system hyperactivity,
  such as gastrointestinal complaints, are
  common and contribute to the high frequency
  with which the patients are seen in outpatient
  medical clinics.
Anxiety disorder
Treatment
• the anxiolytic drugs, some data indicate that
  the use of triazolobenzodiazepines
  (e.g., alprazolam [Xanax]) may be indicated
  because of their effectiveness in treating
  depression associated with anxiety

More Related Content

PPTX
Pain disorder
PPTX
Somatization disorder
PPTX
Manic depressive psychosis (bipolar disease)
PPTX
Dissociative disorder
PPTX
Hallucination
PPTX
Hypochondriasis by RITIKA SONI
PPTX
Depressive disorder (Depression Made Easy!)
PDF
Anxiety disorders
Pain disorder
Somatization disorder
Manic depressive psychosis (bipolar disease)
Dissociative disorder
Hallucination
Hypochondriasis by RITIKA SONI
Depressive disorder (Depression Made Easy!)
Anxiety disorders

What's hot (20)

PPTX
Mood disorder
PPT
Somatoform disorders
PPTX
PPTX
Agoraphobia
PPTX
Special Kinds of Hallucinations
PPT
Pain Disorder
PPT
psychiatry.Somatoform disorders animation part i.(dr.nzar)
PPT
Mood Disorders
PPTX
PPTX
Group therapy
PPTX
Delusions
PPTX
Schizophrenia
PDF
obsessive compulsive and related disorders (OCD)
PPT
Neurotic disorder
PPT
Somatoform disorders (psychophysical problems)
PPTX
Anxiety disorder
PPTX
Management of schizophrenia
PPTX
Disorders Of Perception
PPTX
Schenider first rank symptoms
PPTX
Dependent Personality Disorder -DSM5
Mood disorder
Somatoform disorders
Agoraphobia
Special Kinds of Hallucinations
Pain Disorder
psychiatry.Somatoform disorders animation part i.(dr.nzar)
Mood Disorders
Group therapy
Delusions
Schizophrenia
obsessive compulsive and related disorders (OCD)
Neurotic disorder
Somatoform disorders (psychophysical problems)
Anxiety disorder
Management of schizophrenia
Disorders Of Perception
Schenider first rank symptoms
Dependent Personality Disorder -DSM5
Ad

Viewers also liked (20)

PPTX
Anxiety: causes, symptoms and treatments
PPTX
Anxiety Disorder: Symptoms, Diagnostic Criteria N Treatment
PPTX
Anxiety disorders-
PPT
Chapter 4 anxiety disorders
PPTX
Anxiety Disorders
PPTX
Anxiety disorders for undergraduates
PPTX
Anxiety disorders
PPTX
Generalized Anxiety Disorder (GAD)
PPTX
Presentation 410 ppt on Anxiety
PPTX
Anxiety disorder
PPT
Understanding Generalized Anxiety Disorder
PPT
Stress and anxiety 2012
PPT
Dealing with Anxiety in the Classroom
PPTX
Generalized anxiety disorder
PPTX
Biological therapies anticonvulsant
PDF
Anxiety disorders
PPT
Generalized anxiety disorder
PPTX
Generalized Anxiety Disorder- What It Is And How To Treat It
Anxiety: causes, symptoms and treatments
Anxiety Disorder: Symptoms, Diagnostic Criteria N Treatment
Anxiety disorders-
Chapter 4 anxiety disorders
Anxiety Disorders
Anxiety disorders for undergraduates
Anxiety disorders
Generalized Anxiety Disorder (GAD)
Presentation 410 ppt on Anxiety
Anxiety disorder
Understanding Generalized Anxiety Disorder
Stress and anxiety 2012
Dealing with Anxiety in the Classroom
Generalized anxiety disorder
Biological therapies anticonvulsant
Anxiety disorders
Generalized anxiety disorder
Generalized Anxiety Disorder- What It Is And How To Treat It
Ad

Similar to Anxiety disorder (20)

PPTX
Treatment of schizophrenia
PPTX
PPTX
ANXIETY.pptx
PPTX
Depression & epilepsy
PPTX
Therapeutics II-Affective Disorders.pptx
PPTX
Hanipsych,ofc
PPTX
Panic attack and panic disorder
PPTX
Anxiety disorders
PPTX
Panic disorder
PPTX
Antianxiety drugs pharmacology
PPTX
Psychiatry course-Mood disorders-part-2 (2023)
PPTX
Anxiety disorder (panic disorder)
PPTX
Anxiety disorders
PPTX
Psychosomatic disorders
PPTX
Mental Health Common Mental Disorders RNTU 3rd Mar 2025.pptx
PPTX
Anxiety Disorders Seminar.pptx
PPTX
depression in children with the CLD.pptx
PPTX
Depressive disorders
PPTX
ANXIETY DISORDERS-PHOBIAS.ppt_20241210_152350_0000.pptx
PPTX
Mood disorders
Treatment of schizophrenia
ANXIETY.pptx
Depression & epilepsy
Therapeutics II-Affective Disorders.pptx
Hanipsych,ofc
Panic attack and panic disorder
Anxiety disorders
Panic disorder
Antianxiety drugs pharmacology
Psychiatry course-Mood disorders-part-2 (2023)
Anxiety disorder (panic disorder)
Anxiety disorders
Psychosomatic disorders
Mental Health Common Mental Disorders RNTU 3rd Mar 2025.pptx
Anxiety Disorders Seminar.pptx
depression in children with the CLD.pptx
Depressive disorders
ANXIETY DISORDERS-PHOBIAS.ppt_20241210_152350_0000.pptx
Mood disorders

More from Nilesh Kucha (20)

PDF
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
PPTX
Chapter 39 role of radiotherapy in benign diseases
PDF
Chapter 39 role of radiotherapy in benign diseases
PPTX
Chapter 38 role of surgery in cancer prevention
PPTX
Chapter 37 svco
PPTX
Chapter 36 t reg cells
PPTX
Chapter 35 tumor lysis syndrome
PPTX
Chapter 34 medical stat
PPTX
Chapter 33 isolated tumor cells
PPTX
Chapter 32 invasion and metastasis
PPTX
Chapter 31 genetic counselling
PPTX
Chapter 30 febrile neutropenia
PPTX
Chapter 29 dendritic cells
PPT
Chapter 28 clincal trials
PPTX
Chapter 27 chemotherapy side effects dr lms
PPTX
Chapter 26 chemoprevention of cancer
PPTX
Chapter 25 assessment of clincal responses
PPT
Chapter 24.3 metronomic chemotherapy
PPTX
Chapter 24.2 lmwh in cancer asso thrombosis
PPTX
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
Chapter 38 role of surgery in cancer prevention
Chapter 37 svco
Chapter 36 t reg cells
Chapter 35 tumor lysis syndrome
Chapter 34 medical stat
Chapter 33 isolated tumor cells
Chapter 32 invasion and metastasis
Chapter 31 genetic counselling
Chapter 30 febrile neutropenia
Chapter 29 dendritic cells
Chapter 28 clincal trials
Chapter 27 chemotherapy side effects dr lms
Chapter 26 chemoprevention of cancer
Chapter 25 assessment of clincal responses
Chapter 24.3 metronomic chemotherapy
Chapter 24.2 lmwh in cancer asso thrombosis
Chapter 24.1 kinase inhibitors and monoclonal antibodies

Anxiety disorder

  • 1. Generalized Anxiety Disorder • Anxiety can be conceptualized as a normal and adaptive response to threat that prepares the organism for flight or fight • Persons who seem to be anxious about almost everything, however, are likely to be classified as having generalized • anxiety disorder associated with somatic symptoms, such as muscle tension, irritability, difficulty sleeping, and restlessness
  • 2. • The anxiety is not focused on features of another Axis I disorder, is not caused by substance use or a general medical condition, and does not occur only during a mood or psychiatric disorder.
  • 3. Epidemiology • Generalized anxiety disorder is a common condition; reasonable estimates for its 1-year prevalence range from 3 to 8 percent. • The ratio of women to men with the disorder is about 2 to 1, but the ratio of women to men who are receiving inpatient treatment for the disorder is about 1 to 1. A lifetime prevalence is close to 5 percent with the Epidemiological Catchment Area (ECA) study suggesting a lifetime prevalence as high as 8 percent.
  • 4. • In anxiety disorder clinics about 25 percent of patients have generalized anxiety disorder. The disorder usually has its onset in late adolescence or early adulthood, although cases are commonly seen in older adults • Also, some evidence suggests that the prevalence of generalized anxiety disorder is particularly high in primary care settings
  • 5. Comorbidity • Generalized anxiety disorder coexists with another mental disorder, usually social phobia, specific phobia, panic disorder, or a depressive disorder • As many as 25 percent of patients eventually experience panic disorder. Generalized anxiety disorder is differentiated from panic disorder by the absence of spontaneous panic attacks.
  • 6. Biological Factors • benzodiazepines and the azaspirones (e.g., buspirone [BuSpar]) have focused biological research efforts on the γ-aminobutyric acid and serotonin neurotransmitter systems • Benzodiazepines (which are benzodiazepine receptor agonists) are known to reduce anxiety
  • 7. • Where as flumazenil (Romazicon) (a benzodiazepine receptor antagonist) and the β-carbolines (benzodiazepine receptor reverse agonists) are known to induce anxiety.
  • 11. Treatment • The most effective treatment of generalized anxiety disorder is probably one that combines psychotherapeutic, pharmacotherapeutic, and supportive approaches.
  • 12. Psychotherapy • The major techniques used in behavioral approaches are relaxation and biofeedback • Insight-oriented psychotherapy focuses on uncovering unconscious conflicts and identifying ego strengths • Psychodynamic therapy proceeds with the assumption that anxiety can increase with effective treatment. The goal of the dynamic approach may be to increase the patient's anxiety tolerance (a capacity to experience anxiety without having to discharge it), rather than to eliminate anxiety
  • 13. Pharmacotherapy I. Benzodiazepines II. Buspirone III. Venlafaxine IV. Selective Serotonin Reuptake Inhibitors V. Other drugs
  • 14. Anxiety Disorder due to a General Medical Condition
  • 15. Etiology • A wide range of medical conditions can cause symptoms similar to those of anxiety disorders (Table 16.7-1). Hyperthyroidism, hypothyroidism, hypoparath yroidism, and vitamin B12 deficiency are frequently associated with anxiety symptoms • A pheochromocytoma produces epinephrine, which can cause paroxysmal episodes of anxiety symptoms
  • 18. Generalized Anxiety • generalized anxiety disorder symptoms has been reported in patients with sjogren’s syndrome, and this rate may be related to the effects of sjogren’s syndrome on cortical and subcortical functions and thyroid function • generalized anxiety disorder symptoms in a medical disorder seems to be in Graves' disease
  • 19. Phobias • 17 percent prevalence of symptoms of social phobia in patients with Parkinson's disease • patients complain of a fear of falling, which may express itself by their being unwilling or fearful of walking
  • 20. Differential Diagnosis • A mental status examination is necessary to determine the presence of mood symptoms or psychotic symptoms that may suggest another psychiatric diagnosis • For a clinician to conclude that a patient has an anxiety disorder caused by a general medical condition, the patient should clearly have anxiety as the predominant symptom and should have a specific causative nonpsychiatric medical disorder
  • 21. Treatment • the removal of the primary medical condition does not reverse the anxiety disorder symptoms, treatment of these symptoms should follow the treatment guidelines for the specific mental disorder • In general, behavioral modification techniques, anxiolytic agents, and serotonergic antidepressants have been the most effective treatment modalities
  • 22. Substance-Induced Anxiety Disorder • Substance-induced disorder is the direct result of a toxic substance, including drugs of abuse, medication, poison, and alcohol, among others.
  • 23. Etiology • as amphetamine, cocaine, and caffeine, have been most associated with the production of anxiety disorder symptoms, many serotonergic drugs (e.g., lysergic acid diethylamide [LSD] and methylenedioxymethamphetamine [MDMA]) can also cause both acute and chronic anxiety syndromes in users • wide range of prescription medications
  • 26. Clinical Features • Nevertheless, alcohol use disorders and other substance-related disorders are commonly associated with anxiety disorders. • Alcohol use disorders are about four times more common among patients with panic disorder than among the general population, about three and a half times more common among patients with OCD, and about two and a half times more common among patients with phobias
  • 27. Course and Prognosis • The course and prognosis generally depend on removal of the causally involved substance and the long-term ability of the affected person to limit use of the substance. • The anxiogenic effects of most drugs are reversible. • When the anxiety does not reverse with cessation of the drug, clinicians should reconsider the diagnosis of substance-induced anxiety disorder or consider the possibility that the substance caused irreversible brain damage.
  • 28. Treatment • anxiety disorder symptoms continue even after stopping substance use, treatment of the anxiety disorder symptoms with appropriate psychotherapeutic or pharmacotherapeutic modalities may be appropriate
  • 29. Anxiety Disorder not Otherwise Specified
  • 30. Mixed Anxiety-Depressive Disorder • Mixed anxiety-depressive disorder describes patients with both anxiety and depressive symptoms who do not meet the diagnostic criteria for either an anxiety disorder or a mood disorder. • The combination of depressive and anxiety symptoms results in significant functional impairment for the affected person. • The condition may be particularly prevalent in primary care practices and outpatient mental health clinics
  • 31. Diagnosis • anxiety and depression and the presence of some autonomic symptoms, such as tremor, palpitations, dry mouth, and the sensation of a churning stomach.
  • 32. Clinical Features • anxiety disorders and some symptoms of depressive disorders are common symptoms of autonomic nervous system hyperactivity, such as gastrointestinal complaints, are common and contribute to the high frequency with which the patients are seen in outpatient medical clinics.
  • 34. Treatment • the anxiolytic drugs, some data indicate that the use of triazolobenzodiazepines (e.g., alprazolam [Xanax]) may be indicated because of their effectiveness in treating depression associated with anxiety